TANGO: Wk 144 Analysis of Switch to DTG/3TC vs Continued 3-Drug or 4-Drug TAF-Based Regimen

Source: IDWeek 2021: Clinical Impact of New Data*
Download Slideset
September 29 - October 3, 2021; Virtual
Switching to DTG/3TC continues to show high levels of virologic suppression, favorable safety and tolerability, and a high barrier to resistance through 3 years.
Format: Microsoft PowerPoint (.ppt)
File Size: 489 KB
Released: October 5, 2021

Acknowledgements

Provided by Clinical Care Options, LLC.
Contact Info

Contact Clinical Care Options

For customer support please email: customersupport@cealliance.com

Mailing Address
Clinical Care Options, LLC
12001 Sunrise Valley Drive
Suite 300
Reston, VA 20191

Supported by educational grants from
Gilead Sciences, Inc.
Janssen Therapeutics, Division of Janssen Products, LP
ViiV Healthcare

Leaving the CCO site

You are now leaving the CCO site. The new destination site may have different terms of use and privacy policy.

Continue

Cookie Settings